PL3117837T3 - Formulacje przeciwciała - Google Patents

Formulacje przeciwciała

Info

Publication number
PL3117837T3
PL3117837T3 PL16180643T PL16180643T PL3117837T3 PL 3117837 T3 PL3117837 T3 PL 3117837T3 PL 16180643 T PL16180643 T PL 16180643T PL 16180643 T PL16180643 T PL 16180643T PL 3117837 T3 PL3117837 T3 PL 3117837T3
Authority
PL
Poland
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
PL16180643T
Other languages
English (en)
Inventor
Xinghang Ma
Jun Xiang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/601,598 external-priority patent/US8613919B1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PL3117837T3 publication Critical patent/PL3117837T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16180643T 2012-08-31 2013-08-28 Formulacje przeciwciała PL3117837T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/601,598 US8613919B1 (en) 2012-08-31 2012-08-31 High concentration antibody and protein formulations
US13/843,780 US9592297B2 (en) 2012-08-31 2013-03-15 Antibody and protein formulations
EP13760179.5A EP2890718A1 (en) 2012-08-31 2013-08-28 Antibody and protein formulations
PCT/US2013/056970 WO2014036071A1 (en) 2012-08-31 2013-08-28 Antibody and protein formulations
EP16180643.5A EP3117837B1 (en) 2012-08-31 2013-08-28 Antibody formulations

Publications (1)

Publication Number Publication Date
PL3117837T3 true PL3117837T3 (pl) 2020-02-28

Family

ID=49162239

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16180643T PL3117837T3 (pl) 2012-08-31 2013-08-28 Formulacje przeciwciała

Country Status (25)

Country Link
US (7) US9592297B2 (pl)
EP (3) EP3590536A1 (pl)
JP (3) JP6462567B2 (pl)
CN (2) CN114392353A (pl)
AR (2) AR092388A1 (pl)
AU (3) AU2013308902B2 (pl)
BR (1) BR112015003838A2 (pl)
CA (2) CA3129277A1 (pl)
CY (1) CY1121989T1 (pl)
DK (1) DK3117837T3 (pl)
ES (1) ES2741575T3 (pl)
HR (1) HRP20191299T1 (pl)
HU (1) HUE045652T2 (pl)
IL (6) IL294567A (pl)
LT (1) LT3117837T (pl)
MX (2) MX369653B (pl)
PL (1) PL3117837T3 (pl)
PT (1) PT3117837T (pl)
RS (1) RS59221B1 (pl)
RU (2) RU2019100887A (pl)
SG (2) SG11201501116RA (pl)
SI (1) SI3117837T1 (pl)
TW (4) TW201414496A (pl)
UY (1) UY34995A (pl)
WO (1) WO2014036071A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6170903B2 (ja) * 2011-04-01 2017-07-26 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
AT512589B1 (de) * 2012-03-12 2014-06-15 Zizala Lichtsysteme Gmbh Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
KR102594117B1 (ko) 2014-10-01 2023-10-26 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
KR20230074843A (ko) 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CA2999118C (en) * 2015-09-22 2022-06-14 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
CR20180599A (es) 2016-06-30 2019-04-09 Celltrion Inc Preparación farmacéutica líquida estable
CA3030422C (en) 2016-07-13 2021-10-26 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
CN109982716B (zh) 2016-09-16 2024-05-10 白血球保健股份有限公司 在加工过程中稳定生物制药药物产品的新方法
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
US20200131251A1 (en) * 2016-12-23 2020-04-30 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US20210292434A1 (en) * 2018-07-05 2021-09-23 Bayer Aktiengesellschaft NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
JP7467438B2 (ja) * 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
SG11202108627SA (en) * 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
MA55809B1 (fr) * 2019-05-01 2025-12-31 Novo Nordisk A/S Formulations d'anticorps anti-il-6
CN114786717B (zh) * 2019-11-13 2024-12-17 辉瑞公司 稳定的水性抗-tfpi抗体制剂
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
BR112022026482A2 (pt) * 2020-07-03 2023-01-31 CSL Innovation Pty Ltd Formulação altamente concentrada de proteínas de ligação ao antígeno do fator xii
JP2025515325A (ja) * 2022-04-29 2025-05-14 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｉｌｔ４抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
EP4562039A1 (en) * 2022-07-27 2025-06-04 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4912861A (en) * 1988-04-11 1990-04-03 Huang Ing Chung Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK0686045T3 (da) 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
ES2208884T3 (es) 1996-01-25 2004-06-16 Schering Aktiengesellschaft Soluciones mejoradas de agentes de contraste para la administracion intravasal.
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999011091A1 (de) 1997-08-21 1999-03-04 Siemens Aktiengesellschaft Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
AU2001236005A1 (en) 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP1272211B1 (en) 2000-04-07 2007-06-06 Signal Coordinating Therapy, Inc. Methods and compositions for treating neoplasms
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
KR20030027077A (ko) 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
CN1604788B (zh) 2001-10-16 2013-04-17 里克斯金蒂克斯公司 高浓度蛋白制剂及其制备方法
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
WO2005123131A2 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CA2490423A1 (en) 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20050276823A1 (en) 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经系统学公司 抗ngf抗体及其使用方法
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1849138B (zh) 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AR054428A1 (es) 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
CN101166763B (zh) * 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
AU2006261920A1 (en) * 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
DK1899462T3 (da) 2005-07-02 2011-06-06 Arecor Ltd Stabile vandige systemer omfattende proteiner
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
BRPI0618850A2 (pt) 2005-11-21 2011-09-13 Sanofi Pasteur Ltd formulações de estabilização para vìrus recombinantes
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
EP2029163A4 (en) 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
BRPI0721097A2 (pt) * 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
ES2707815T3 (es) 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
US20110014203A1 (en) 2007-12-28 2011-01-20 Fredrik Nilsson Formulation
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
MX2010013565A (es) 2008-06-30 2011-01-14 Novo Nordisk As Anticuerpos de interleucina-20 anti-humanos.
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
TR201802935T4 (tr) 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JPWO2011108452A1 (ja) * 2010-03-02 2013-06-27 Jnc株式会社 還元反応器
EP2547355B1 (en) * 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
MX2012013586A (es) * 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
PL2624865T3 (pl) * 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JP6170903B2 (ja) 2011-04-01 2017-07-26 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
TW201825116A (zh) 2018-07-16
IL286784B (en) 2022-08-01
SG11201501116RA (en) 2015-04-29
CY1121989T1 (el) 2020-10-14
WO2014036071A1 (en) 2014-03-06
IL265865A (en) 2019-06-30
EP2890718A1 (en) 2015-07-08
JP2021059602A (ja) 2021-04-15
TW201927338A (zh) 2019-07-16
IL294567A (en) 2022-09-01
IL265864B (en) 2020-02-27
JP6462567B2 (ja) 2019-01-30
EP3117837A1 (en) 2017-01-18
US20210077381A1 (en) 2021-03-18
TW201424748A (zh) 2014-07-01
MX369653B (es) 2019-11-15
RU2015111341A (ru) 2016-10-27
IL286784A (en) 2021-10-31
CN104684933A (zh) 2015-06-03
AU2013308902A1 (en) 2015-03-12
US20180028669A1 (en) 2018-02-01
TWI609697B (zh) 2018-01-01
EP3590536A1 (en) 2020-01-08
CA2883095C (en) 2021-10-26
CN104684933B (zh) 2021-11-30
AU2018203320A1 (en) 2018-05-31
HRP20191299T1 (hr) 2019-10-18
ES2741575T3 (es) 2020-02-11
CN114392353A (zh) 2022-04-26
UY34995A (es) 2014-03-31
HUE045652T2 (hu) 2020-01-28
EP3117837B1 (en) 2019-05-22
US20140065159A1 (en) 2014-03-06
US20150030591A1 (en) 2015-01-29
SG10201708215YA (en) 2017-11-29
AR092400A1 (es) 2015-04-22
AR092388A1 (es) 2015-04-22
IL279237A (en) 2021-01-31
CA3129277A1 (en) 2014-03-06
AU2013308902B2 (en) 2018-04-12
AU2018203320B2 (en) 2020-02-27
US9849181B2 (en) 2017-12-26
US20230190637A9 (en) 2023-06-22
TW201414496A (zh) 2014-04-16
RU2678097C2 (ru) 2019-01-23
HK1210794A1 (zh) 2016-05-06
JP2019048886A (ja) 2019-03-28
LT3117837T (lt) 2019-09-25
BR112015003838A2 (pt) 2017-07-04
MX2015002411A (es) 2015-06-05
MX2019013670A (es) 2020-01-15
RU2019100887A3 (pl) 2019-08-27
IL265864A (en) 2019-06-30
AU2020200134A1 (en) 2020-01-30
CA2883095A1 (en) 2014-03-06
US20140105892A1 (en) 2014-04-17
RU2019100887A (ru) 2019-03-22
DK3117837T3 (da) 2019-08-19
US20150209431A1 (en) 2015-07-30
IL237188A0 (en) 2015-04-30
US20180055940A1 (en) 2018-03-01
US9592297B2 (en) 2017-03-14
JP2015528464A (ja) 2015-09-28
PT3117837T (pt) 2019-08-26
RS59221B1 (sr) 2019-10-31
SI3117837T1 (sl) 2019-10-30

Similar Documents

Publication Publication Date Title
IL276234B (en) Antibody compositions
IL264558A (en) Anti–il–23p19 antibodies
HUE045652T2 (hu) Antitest-készítmények
IL235966A0 (en) Antibody formulation
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL235042B (en) Anti–fcrn antibodies
IL234848A0 (en) Protease controlled antibodies
IL236259A0 (en) Anti 15–siglec antibodies
ZA201407316B (en) Anti-fgfr2 antibody
SG10201709290XA (en) Anti-H7cr Antibodies
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
GB201220242D0 (en) Antibody
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201206178D0 (en) Formulations
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations